Journal For Clinical Studies
Journal For Clinical Studies

SEARCH

MEDIA PACK
NEWS

MENU

Current Edition

 
antibody

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and …

13 December 2017 news antibody autoimmune
Continue Reading →
 
jcs-white

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Twitter Linkedin
Journal For Clinical Studies © 2022, All Rights Reserved – Powered by Teksyte